Detalhe da pesquisa
1.
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Leukemia
; 38(6): 1307-1314, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38678093